Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 6/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13706699 | 0.80 | OPRK1 (0.39) | OPRK1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL9908407 | 0.79 | MEN1 (0.35) | OPRK1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL20825675 | 0.79 | MEN1 (0.39) | OPRK1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL22580075 | 0.79 | MEN1 (0.39) | OPRK1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL22552943 | 0.79 | ALDH1A1 (0.37) | OPRK1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL22552942 | 0.79 | ALDH1A1 (0.37) | OPRK1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL26935787 | 0.78 | OPRK1 (0.36) | OPRK1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL19217994 | 0.77 | OPRK1 (0.35) | OPRK1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL25233759 | 0.76 | MEN1 (0.41) | OPRK1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL21626126 | 0.73 | OPRK1 (0.37) | OPRK1MEN1NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424829-B1 | OMEGA-CYCLOHEXYLALKAN-1-OLES AND USE THEREOF AS ANTIMICROBIAL ACTIVES TO COMBAT BODY ODOR | SYMRISE AG (DE) | 2015-01-07 | — | — | EP | disclosed |
| US-8623340-B2 | Omega-cyclohexylalkan-1-oles and use thereof as antimicrobial actives to combat body odor | SYMRISE AG (DE) | 2014-01-07 | — | — | US | disclosed |
| US-20120107258-A1 | OMEGA-CYCLOHEXYLALKAN-1-OLES AND USE THEREOF AS ANTIMICROBIAL ACTIVES TO COMBAT BODY ODOR | SYMRISE AG (DE) | 2012-05-03 | — | — | US | disclosed |
| EP-2424829-A2 | OMEGA-CYCLOHEXYLALKAN-1-OLES AND USE THEREOF AS ANTIMICROBIAL ACTIVES TO COMBAT BODY ODOR | Symrise AG (DE) | 2012-03-07 | — | — | EP | disclosed |
| WO-2009101216-A2 | OMEGA-CYCLOHEXYLALKAN-1-OLES AND USE THEREOF AS ANTIMICROBIAL ACTIVES TO COMBAT BODY ODOR | SYMRISE GMBH & CO. KG (DE) | 2009-08-20 | — | — | WO | disclosed |
| US-20090123392-A1 | FRAGRANCE ACCORDS TO COMBAT THE PERCEPTION OF BODY ODOR | SYMRISE GMBH & CO. KG (DE) | 2009-05-14 | — | — | US | disclosed |
| EP-2014273-A1 | Use of methyl methyl ether and another ether to provide a feeling of cleanliness and purity | Symrise GmbH & Co. KG (DE) | 2009-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120107258-A1 | OMEGA-CYCLOHEXYLALKAN-1-OLES AND USE THEREOF AS ANTIMICROBIAL ACTIVES TO COMBAT BODY ODOR | ALOX12, ALOX15, ALOX15B | OPRK1 50/4885MEN1 4068/4885NPC1 1941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.